Trial
NCT00000961
The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Abbott; Glaxo Wellcome
Condition
HIV Infections
Intervention
Anti-HIV Immune Serum Globulin (Human)
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-04